Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived MSC injections for hip osteoarthritis
ACTRN12615000260527Phase 2Terminated
- Sponsor
- Magellan Stem Cells
- Start
- Feb 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in hip osteoarthritis and osteoarthritis (OA), sponsored by Magellan Stem Cells. Primary endpoints: Hip Injury and Osteoarthritis Outcome Score at 12 months, Numerical Pain Rating Scale at 12 months and 1 more. Started Feb 2016; status: terminated.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
hip osteoarthritisosteoarthritis (OA)
Beyond the preview
Go deeper on ACTRN12615000260527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000260527.